

IFW #

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**



In re Application of

**HOLLA et al.**

Examiner: Susannah E. Lee

Art Unit: 1626

Application No.: **10/789,053**

Filed: **February 27, 2004**

Title: **PROCESS FOR PREPARING THE  
ENANTIOMERIC FORMS OF CIS-  
CONFIGURED 1,3-  
CYCLOHEXANEDIOL DERIVATIVES**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 15, 2005

Date of Deposit

Brian Pritchett  
Signature

*Brian Pritchett*

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

09/21/2005 EAYALEW1 00000020 181982 10789053

01 FC:1806 180.00 DA

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



Barbara E. Kurys, Reg. No., 34,640  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2003/0014 US NP



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

**HOLLA et al.**

Examiner: Susannah E. Lee

Art Unit: 1626

Application No.: **10/789,053**

Filed: **February 27, 2004**

Title: **PROCESS FOR PREPARING THE  
ENANTIOMERIC FORMS OF CIS-  
CONFIGURED 1,3-CYCLOHEXANEDIOL  
DERIVATIVES**

**Certificate of Mailing or Transmission**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit September 15, 2005

Printed Name of Person Signing Certificate Brian Pritchett

Signature Brian Pritchett


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. **18-1982** in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,

  
Barbara E. Kurys, Reg. No. 34,650  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0014 US NP



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 4

<b>Application Number</b>	10/789,053
<b>Filing Date</b>	02-27-2004
<b>First Named Inventor</b>	HOLLA et al.
Group Art Unit	1626
<b>Examiner Name</b>	LEE, Susannah E.
<b>Attorney Docket Number</b>	DEAV2003/0014 - US - NP

[illegible][illegible]Date  
Considered

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/789,053
		<b>Filing Date</b>	02-27-2004
		<b>First Named Inventor</b>	HOLLA et al.
		<b>Group Art Unit</b>	1626
		<b>Examiner Name</b>	LEE, Susannah E.
<b>Sheet</b>	2	<b>of</b>	4
		<b>Attorney Docket Number</b>	DEAV2003/0014 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BAJWA Joginder S. et al., In-situ generation of Et <sub>3</sub> SiBr from BiBr <sub>3</sub> and Et <sub>3</sub> SiH and its use in preparation of dialkyl ethers, Tetrahedron Letters, (2002), Vol. 43, pp. 6709 - 6713	
		BARTELS Birgit et al., A Selectivity Study Of Activated Ketal Reduction With Borane Dimethyl Sulfide, Journal of Organic Chemistry, (1993), Vol. 58, pp. 6756 - 6765	
		BRINKMAN John A. et al., Trifluoromethyl-Substituted Indenyl Rhodium and Iridium Complexes Are Highly Selective Catalysts for Directed Hydroboration Reactions, Organic Letters, (2000), Vol. 2, No. 7, pp. 981 - 983	
		CARDA M. et al., Enantiotoposelective Ple-Catalyzed Hydrolysis of Cis-5-Substituted-1,3-Diacetoxycyclohexanes. Preparation of Some Useful Chiral Building Blocks, Tetrahedron Asymmetry, (1990), Vol. 1, No. 1, pp. 17 - 20	
		CROTTI Paolo et al., Regiochemical Control of the Ring Opening of 1,2-Epoxydes by Means of Chelating Process. Part 14: Regioselectivity of the Opening Reactions with MeOH of Remote O-Substituted 1,2-Epoxy-cyclohexanes under Gas-Phase Operating Conditions, Tetrahedron, (2000), Vol. 56, pp. 7513 - 7524	
		DAVIES William et al., The Chlorination and Bromination of the Toluic Acids and the Preparation of the Phthalaldehydic Acids, Journal of Chemical Soc., (1922), Vol. 121, pp. 2202 - 2215	
		DUMORTIER L. et al., Revision of the enantiotoposelective PLE-catalyzed hydrolysis of cis-5-substituted-1,2-diacetoxycyclohexanes, Tetrahedron: Asymmetry, (1991), Vol. 2, No. 8, pp. 789 - 792	
		GARRETT Christine E. et al., Exploiting n <sup>5</sup> -- to n <sup>3</sup> Indenyl Ring Slippage to Access a Directed Reaction: Ether-Directed, Rhodium-Catalyzed Olefin Hydroboration, Journal of Organic Chemistry, (1998), Vol. 63, pp. 1370 - 1371	
		GOTO Yoshinobu et al., Studies on Azole Compounds III Reactions of Oxazole N-Oxides with Phosphoryl Chloride and Acetic Anhydride, Chem. Pharm. Bull., (1971), Vol. 19, No. 10, pp. 2050 - 2057	
		GRUBER-KHADJAWI Mandana et al., Chemoenzymatic Methods for the Preparation of Optically Active Cyclic Polyazido Alcohols from Easily Available Achiral Starting Materials, Tetrahedron Asymmetry, (1996), Vol. 7, No. 3, pp. 807 - 814	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/789,053
				Filing Date	02-27-2004
				First Named Inventor	HOLLA et al.
				Group Art Unit	1626
				Examiner Name	LEE, Susannah E.
Sheet	3	of	4	Attorney Docket Number	DEAV2003/0014 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HUBGERHOFF Benno et al., Combining Lipase-Catalyzed Enantiomer-Selective Acylation with Fluorous Phase Labeling: A New Method for the Resolution of Racemic Alcohols, J. Org. Chem., (2002), Vol. 67, pp. 1781 - 1785	
		KUNZ Horst et al., Das System 2-Halogenethylester/Cholinester als Zweistufen-Schutzgruppe für die Carboxylfunktion von Aminosäuren und Peptiden, Chem. Ber., (1979), Vol. 112, pp. 2145 - 2157	
		LAROCK Richard C., Comprehensive Organic Transformations: A Guide To Functional Group Preparations - Acid Halides to Acid Anhydrides	
		LAROCK Richard C., Comprehensive Organic Transformations: A Guide To Functional Group Preparations - Halogenations Of Alcohols	
		LAROCK Richard C., Comprehensive Organic Transformations: A Guide To Functional Group Preparations - Halogenations Of Hydrocarbons	
		MATTSON Anders et al., Kinetic Resolution of Chiral Auxiliaries with C2-Symmetry by Lipase-Catalyzed Alcoholysis and Aminolysis, Acta Chemica Scandinavica, (1996), Vol. 50, pp. 918 - 921	
		PERKIN William Henry et al., An Investigation Of The Action Of Halogens on 2:4-Dimethylbenzoyl Chloride	
		SCHELHAAS Michael et al., Enzymatische Synthese von Peptiden und Ras-Lipopeptiden unter Verwendung des Cholinesters als Löslichkeitsvermittelnder Schutz und Aktivierungsgruppe, Angew. Chem., (1996), pp. 82 - 85	
		SUEMUNE Hiroshi et al., Enantioselective Synthesis of (1S, 3S, 5R)-1-Acetoxy-5-benzyl-oxycyclohexan-3-ol and Its Application to the Synthesis of Compactin Lactone Moiety and Quinic Acid, Tetrahedron Asymmetry, (1992), Vol. 3, No. 2, pp. 297 - 306	
		WIRZ Beat et al., Multiselective enzymatic reactions for the synthesis of protected homochiral cis - and trans-1,3,5-cyclohexanetriols, Tetrahedron: Symmetry, (2000), Vol. 11, pp. 4171 - 4178	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/789,053
				Filing Date	02-27-2004
				First Named Inventor	HOLLA et al.
				Group Art Unit	1626
				Examiner Name	LEE, Susannah E.
Sheet	4	of	4	Attorney Docket Number	DEAV2003/0014 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		YAMANO Toru et al., A Practical Method for Optical Resolution of Racemic Alcohols or Esters via Lipase-Catalyzed Transformation and Sulfation, Chemistry Letters, (2000), pp. 448 - 449	
		ZHAO Yurui et al., Asymmetrization of all-cis-3,5-dihydroxy-1-(methoxycarbonyl)cyclohexane and of the 4-methyl and 4-ethyl substituted homologues, Tetrahedron: Asymmetry, (2000), Vol. 11, pp. 3887 - 3900	
		, Die Delepine-Reaktion bei 2-Aryl-4-chlormethyl-oxazolen	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.